Zacks Research Forecasts Increased Earnings for Teleflex

Teleflex Incorporated (NYSE:TFX) – Stock analysts at Zacks Research upped their FY2024 earnings per share estimates for Teleflex in a report issued on Thursday, November 7th. Zacks Research analyst R. Department now expects that the medical technology company will earn $13.97 per share for the year, up from their previous estimate of $13.88. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q1 2025 earnings at $3.54 EPS, Q3 2025 earnings at $3.78 EPS, Q4 2025 earnings at $4.22 EPS, FY2025 earnings at $15.27 EPS and Q1 2026 earnings at $4.17 EPS.

Several other research analysts also recently commented on TFX. Truist Financial restated a “hold” rating and issued a $227.00 target price (down previously from $255.00) on shares of Teleflex in a research note on Monday, November 4th. Mizuho reduced their price objective on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Stephens increased their target price on shares of Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Teleflex has a consensus rating of “Moderate Buy” and an average price target of $259.25.

Teleflex Price Performance

Shares of NYSE TFX opened at $195.58 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. Teleflex has a fifty-two week low of $194.58 and a fifty-two week high of $257.85. The stock has a market cap of $9.08 billion, a PE ratio of 38.88, a price-to-earnings-growth ratio of 2.00 and a beta of 1.18. The stock has a fifty day moving average of $234.45 and a 200-day moving average of $223.81.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.38 by $0.11. The company had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.64 EPS.

Institutional Investors Weigh In On Teleflex

A number of hedge funds have recently made changes to their positions in TFX. Cerity Partners LLC raised its position in Teleflex by 49.3% in the 3rd quarter. Cerity Partners LLC now owns 13,374 shares of the medical technology company’s stock worth $3,308,000 after purchasing an additional 4,415 shares during the period. Raymond James Trust N.A. grew its stake in shares of Teleflex by 5.4% during the third quarter. Raymond James Trust N.A. now owns 2,110 shares of the medical technology company’s stock valued at $522,000 after buying an additional 108 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Teleflex by 0.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 427,579 shares of the medical technology company’s stock worth $105,749,000 after buying an additional 1,884 shares during the period. Cypress Capital Group bought a new stake in shares of Teleflex in the 3rd quarter valued at about $223,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Teleflex by 37.6% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 42,251 shares of the medical technology company’s stock valued at $10,450,000 after acquiring an additional 11,553 shares during the period. 95.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Teleflex

In other news, Director Stuart A. Randle sold 2,674 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $238.93, for a total value of $638,898.82. Following the completion of the transaction, the director now directly owns 5,496 shares in the company, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.43% of the company’s stock.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be paid a $0.34 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.36 dividend on an annualized basis and a yield of 0.70%. Teleflex’s dividend payout ratio is presently 27.04%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.